ABSTRACT

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Drugs such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) including tocilizumab, have been used to treat autoimmune conditions used in the treatment of covid-19. Remdesivir is a nucleoside analog used to treat RNA virus infections including COVID-19 and is validated using the LC-MS method Favipiravir is an antiviral used to manage influenza, and that has the potential to target other viral infections and favipiravir was validated using the HPLC-UV method. Azithromycin is a macrolide antibiotic used to treat a variety of bacterial infections. Method development and validation for azithromycin were performed using the HPLC method. Dexamethasone is a glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders. Dexamethasone was validated using the RP-HPLC method. Hydroxychloroquine is an antimalarial drug used to treat uncomplicated malaria patients and it was validated using the HPLC method. Omicron is a new variant in covid-19, the rise of the alpha, beta, and delta SARS-CoV-2 VOCs were related to new waves of contaminations, once in a while across worldwide. Keywords: Covid-19 drugs, Remdesivir, Favipiravir, LC-MS, HPLC, variants of Covid 19
Publication date: 01/12/2022

https://ijbpas.com/pdf/2022/December/MS_IJBPAS_2022_6487.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.12.6487